{"id":"W4410151754","doi":"10.1182/bloodadvances.2025015860","title":"ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Servier; Blood Cancer UK; AOP Orphan; Swedish Orphan Biovitrum; Galecto; Novartis Pharma; Astellas Pharma; Incyte; Celgene; AstraZeneca; Pfizer","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Anemia; Neutropenia; Adverse effect; International Prognostic Scoring System; Phases of clinical research; Clinical trial; Gastroenterology; Surgery; Toxicity; Bone marrow; Myelodysplastic syndromes","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008980823,0.0001573264,0.0003846933,0.0001682077,0.00003596802,0.00002202184,0.0001083932,0.00002980866,0.00001799464],"category_scores_gemma":[0.00001310939,0.00009695435,0.00001058862,0.0003660093,0.00004232796,0.0003638062,0.00003367933,0.00007175789,4.49685e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003532962,"about_ca_system_score_gemma":0.00006115684,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004045856,"about_ca_topic_score_gemma":0.004235385,"domain_scores_codex":[0.9990748,0.00002620114,0.0002567541,0.0002754499,0.0002198931,0.0001468765],"domain_scores_gemma":[0.999483,0.00006537705,0.0001107773,0.0002022237,0.0001058203,0.00003277082],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001633187,0.02088477,0.967976,0.00004761856,0.0001389757,0.000003806262,0.001963254,0.00002635783,0.00003956221,0.001228732,0.000001233552,0.006056525],"study_design_scores_gemma":[0.03218023,0.00971528,0.9526167,0.0005592392,0.00008064599,5.232431e-7,0.002396339,0.000006090527,0.002079588,0.0001195663,0.0001449579,0.0001008221],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963479,0.0001693641,0.000009751251,0.0001076263,0.00001681204,0.002074036,0.00001621201,0.0000107123,0.001247578],"genre_scores_gemma":[0.9977754,0.00002183164,0.001612261,0.0001163363,0.000005084961,0.0003662897,0.00002618103,0.00001387668,0.00006276126],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03054704,"threshold_uncertainty_score":0.3953683,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01639570833985633,"score_gpt":0.29476738531814,"score_spread":0.2783716769782836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}